Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Whitehawk Therapeutics (WHWK) over the last 6 years, with Q2 2025 value amounting to -$850000.0.

  • Whitehawk Therapeutics' Cash from Financing Activities fell 107701.15% to -$850000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 6002993.63%. This contributed to the annual value of $130000.0 for FY2024, which is 6012.27% down from last year.
  • According to the latest figures from Q2 2025, Whitehawk Therapeutics' Cash from Financing Activities is -$850000.0, which was down 107701.15% from $95.2 million recorded in Q1 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Cash from Financing Activities peaked at $141.7 million during Q3 2021, and registered a low of -$850000.0 during Q2 2025.
  • Moreover, its 5-year median value for Cash from Financing Activities was $70279.0 (2021), whereas its average is $18.2 million.
  • Over the last 5 years, Whitehawk Therapeutics' Cash from Financing Activities had its largest YoY gain of 95211000.0% in 2025, and its largest YoY loss of 107701.15% in 2025.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Cash from Financing Activities stood at $88000.0 in 2021, then crashed by 221.59% to -$107000.0 in 2022, then surged by 174.77% to $80000.0 in 2023, then plummeted by 33.75% to $53000.0 in 2024, then plummeted by 1703.77% to -$850000.0 in 2025.
  • Its Cash from Financing Activities was -$850000.0 in Q2 2025, compared to $95.2 million in Q1 2025 and $53000.0 in Q4 2024.